Contact Us
Drug Search Results
More Filters [+]

GS-9901

Alternative Names: gs-9901, gs9901, gs 9901
Latest Update: 2015-10-19
Latest Update Note: Clinical Trial Update

Product Description

Gilead Sciences was developing gs-9901, an oral PI3K Inhibitor for adults with follicular lymphoma (FL), marginal zone lymphoma (MZL), chronic lymphocytic leukemia (CLL), or small lymphocytic lymphoma (SLL)

Mechanisms of Action: PI3K Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Gilead Sciences
Company Location: FOSTER CITY CA 94404
Company CEO: Daniel P. O’Day
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for GS-9901

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Chronic Lymphoid Leukemia|B-Cell Marginal Zone Lymphoma|Lymphocytic Chronic B-Cell Leukemia|Follicular Lymphoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
GS-US-325-1348

P1

Terminated

Lymphocytic Chronic B-Cell Leukemia|B-Cell Marginal Zone Lymphoma|Chronic Lymphoid Leukemia|Follicular Lymphoma

2015-08-01

Recent News Events

Date

Type

Title

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions